

## INAUGURAL EDITORIAL

# Cancer in Females: A cutting-edge research platform for multidisciplinary collaboration in women's health and oncology

Jinghe Lang\*

Department of Obstetrics and Gynaecology, Peking Union Medical College Hospital, Beijing 100730, China



**Jinghe Lang**, Academician of Chinese Academy of Engineering. Honorary director, professor and doctoral supervisor of Obstetrics and Gynecology Department of Peking Union Medical College Hospital. President of the Chinese Obstetricians and Gynecologists Association, Academician of the International Eurasian Academy of Sciences (CSCIEAS), Honorary Academician of the American College of Obstetricians and Gynecologists (ACOG), Honorary Academician of the Royal College of Obstetricians and Gynecologists (RCOG). President of the Asia Pacific Society of Gynecologic Endoscopy (APAGE), Executive Director of the American Association of Gynecologic Laparoscopists (AAGL) and the European Society of Gynecologic Endoscopy (ESGE). Vice President of the World Chinese Medical Association, President of the World Chinese Association of Obstetrics and Gynecology.

Female cancer, a term referring to malignant tumours occurring within the gender-specific reproductive and urinary systems, as well as other organs, poses a significant threat to women's health globally. Annual diagnoses of malignant tumours run into the millions, profoundly impacting women's health and quality of life. Global data for 2020 indicates 9.23 million new cases of female cancer, of which 2.26 million were breast cancer, far exceeding other female cancers. The top three gynaecological malignancies- cervical, endometrial, and ovarian cancers, ranked 4th, 6th and 8th respectively, accounting for nearly 15% of all new female cancer cases. The same year saw 4.43 million female cancer fatalities worldwide, with breast cancer accounting for 680, 000, making it the deadliest cancer. Cervical and ovarian cancers, both reproductive tract malignancies, ranked 4th and 8th respectively, contributing to 12.4% of all female cancer deaths.

Distinct gender differences exist between female and male cancers in terms of physiology, pathology, and molecular biology. Investigating and summarising these

disparities can guide the understanding of etiology, diagnosis, and treatment, offering theoretical support for personalised medicine. Furthermore, managing and treating female cancer demands a multidisciplinary approach, encapsulating basic science, clinical medicine, radiotherapy, chemotherapy, surgery, mental health, and supportive care. This necessitates a platform that fosters collaboration among researchers from diverse fields, promoting interdisciplinary communication and cooperation. Such a platform can stimulate advances in the prevention and early detection of female cancer, spark innovation in treatment methods and strategies, and ultimately boost research progress and therapeutic outcomes in female cancer, thereby championing women's health.

In light of the current landscape, we are proud to launch "Cancer in Females"(CF), an anticipatory, authoritative, international, and professional journal. Under the stewardship of Academician of China Engineering Academy, Prof. Lang Jinghe from the Department of


**\*Corresponding Author:**

Jinghe Lang, Department of Obstetrics and Gynaecology, Peking Union Medical College Hospital, Beijing 100730, China.

Email: cfjinghelang@163.com. <https://orcid.org/0000-0002-5087-3788>

Received: 26 January 2024; Revised: 26 January 2024; Accepted: 28 January 2024

<https://doi.org/10.54844/cif.2024.0536>

 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which allows others to copy and redistribute the material in any medium or format non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Obstetrics and Gynaecology at Peking Union Medical College Hospital, CF aspires to benchmark the world's leading medical journals. As an open-access, peer-reviewed, English academic journal, CF will be published quarterly, maintaining rigorous peer review processes and publishing standards to ensure high-quality development.

CF is dedicated to focusing on women's health, addressing the critical challenges of major female diseases, and filling a notable void in the realm of English language journals in this field. By concentrating on the latest research in the monitoring, prevention, diagnosis, and treatment of female cancers, CF strives to enhance physicians' and scientists' understanding of female cancer diseases. We aim to foster interest and expertise in related fields, including diagnosis and treatment, nursing, research, education, and public policy. By gathering distinguished scholars from this field both domestically and globally, we aim to build a premier academic platform, playing a pivotal role in shaping the community of global health.

Our journal will feature key sections including commentaries, expert forums, monographs, abstracts, guidelines and

consensus, reviews, experience exchange, short reports, case reports, innovation and debate, experience sharing, academic trends, and continuing education. Looking ahead, our goal is to establish a world-class academic journal rooted in the Asia-Pacific region but with a global reach. We invite you to peruse our journal and trust you will find our publication engaging and informative.

## **DECLARATION**

### ***Author contributions***

Lang JH contributed solely to the Editorial.

### ***Source of funding***

None.

### ***Conflict of interest***

Lang JH is a Co-Editor-in-Chief of the journal. The article was subject to the journal's standard procedures.

### ***Data availability statement***

Not applicable.